Reporting: U.S. BIOSECURE Act

1. BIOSECURE Act Starts Dismantling WuXi 10/16/2024

   Components of the WuXi global organization are for sale. It’s a forced divestiture. WuXi AppTec is marketing some of its U.S. and European operations. The ill-advised BIOSECURE Act targeting several China-based biopharma companies is having its intended effects, even before the legislation is fully passed by the U.S. government. Where do you stand?

2. BIOSECURE Act Passes House. How Will It Impact Your Outsourcing? 9/10/2024

   The U.S. House of Representatives was hell-bent on sending a message to China – and all of us in the biopharma industry. Congress hopes that message – and real-life consequences – will be accomplished via its successfully passing the BIOSECURE Act in a House vote. Breaking analysis from Chief Editor Louis Garguilo. 

3. Warning To U.S.-Based CDMOs: Don't Get Complacent 9/9/2024

   How could I not ask him for an opinion regarding our vigorously pursued editorials on the WuXi Apptec–BIOSECURE Act. After all, Reza Oliyai has outsourced a myriad of development and manufacturing services to hundreds of CDMOs around the world. He did so at Gilead for decades, and since as the CEO  of his eponymous consulting company. His response did not disappoint.

4. Clinical Trials In China Reboot BIOSECURE Act 8/21/2024

   Clinical trials are not my beat, but the BIOSECURE Act targeting CDMOs sure is. Now the congressional committee involved with putting that legislation together has found something of perhaps more substance, and better substantiated, to add to the impetus of the Act: clinical trials in China.

5. Breaking: BIOSECURE Act Out. Long Live Wuxi Apptec? 6/25/2024

   The U.S. House Rules Committee did not include the BIOSECURE Act in the final list of amendments for the National Defense Authorization Act (NDAA). Chief Editor Louis Garguilo has been outspoken in defending WuXi Apptec’s right to due process. Readers have responded in spades. Here's the latest.

6. Assassination By Implication? Interview With WuXi AppTec (Part 2) 5/20/2024

   “As you read these accusations, it’s like an attempted death by a thousand implications,” says Rick Connell, former Pfizer supply-chain executive and current WuXi AppTec President, U.S. and Europe. In this part two, he provides a line-by-line analysis of the BIOSECURE Act targeting his company.

7. Exclusive Interview: WuXi AppTec Responds To BIOSECURE Act 5/13/2024

   Rick Connell, WuXi AppTec’s President, U.S. and Europe, agreed to an exclusive interview with Chief Editor Louis Garguilo to address accusations in the BIOSECURE Act. To understand Connell is to understand the shock at WuXi AppTec – and  among its customers.

8. Nothing To See Here! Just Big Pharma Investments In China 4/22/2024

   WuXi AppTec assists U.S.-based biotechs to develop and supply drugs to U.S. patients. Western-based Pharma assists the development of China's industry, the China Communist Party (CCP) by extension, and patients there. Guess which is under assault? Chief Editor Louis Garguilo tries to figure it all out.

9. You Want To Rein In China? Then Actually Do It 4/12/2024

   Chief Editor Louis Garguilo takes a hard look at proposed legislation H.R. 7085 - the BIOSECURE Act - and draws out some interesting angles and conclusions regarding the biopharma battle between the U.S. and China.

10. From Ally To Adversary: BIO's Swift Rebuke Of WuXi 4/5/2024

    The CEO of the Biotechnology Innovation Organization (BIO) spearheading expulsion of WuXi Apptec relied on WuXi Biologics as CEO of the biotech he founded. More on this and some breaking news on the U.S. government's accusations regarding WuXi, from Chief Editor Louis Garguilo.